Simcere Zaiming licenses SIM0660 to Roche
Analysis based on 11 articles · First reported Jul 20, 2026 · Last updated Sep 01, 2026
The deal is expected to positively impact Grand Pharmaceutical Group's valuation by providing a significant upfront payment and potential milestone-based revenue, while validating its T-cell engager platform. For Roche, the acquisition of a potential first-in-class asset strengthens its oncology and immunology pipeline, though the financial impact will depend on clinical and commercial success.
Grand Pharmaceutical Group — Simcere Zaiming, a subsidiary of Grand Pharmaceutical Group (2096.HK), announced on September 1, 2026 that it entered into an exclusive global licensing agreement with Roche for the development and commercialization of SIM0660, a tri-specific antibody targeting CD79a, CD19, and CD3. Under the terms, Roche acquires exclusive worldwide rights to develop, manufacture, and commercialize SIM0660. Grand Pharmaceutical Group — Simcere Zaiming is eligible to receive up to $1.53 billion in total payments, including a $75 million upfront payment, plus tiered royalties of up to double digits on future net sales. SIM0660 was developed using Grand Pharmaceutical Group — Simcere Zaiming's proprietary T-cell engager poly-specific antibody technology and is designed to treat B-cell-mediated diseases, including certain cancers and autoimmune conditions. The deal extends Grand Pharmaceutical Group's out-licensing track record, which now includes six transactions with potential aggregate consideration exceeding $6.1 billion. Roche's Head of Corporate Business Development, Boris L. Zaitra, and Grand Pharmaceutical Group — Simcere Zaiming's Chairman and CEO, Renhong Tang, both commented positively on the collaboration. The agreement highlights the growing role of Chinese biotech innovation in global pharmaceutical partnerships.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard